文献速递乳腺癌

体重指数正常绝经后女性体脂与乳腺癌风险的关联:一项随机临床试验与观察性研究的二次分析

Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study.
PubMed 文献 · JAMA Oncol · 2019-01-01

该研究对妇女健康倡议(WHI)临床试验与观察性研究中体重指数(BMI)18.5至24.9的3460名绝经后女性进行二次分析,中位随访16年确诊182例浸润性乳腺癌。全身体脂最高四分位与最低四分位相比,浸润性乳腺癌风险升高(HR 1.89,95%CI 1.21-2.95),雌激素受体(ER)阳性乳腺癌风险亦升高(HR 2.21,95%CI 1.23-3.67)。

要点

  • BMI正常绝经后女性中,全身体脂最高四分位者浸润性乳腺癌风险升高,HR 1.89(95%CI 1.21-2.95)。
  • 躯干脂肪最高四分位者ER阳性乳腺癌风险升高,HR 1.98(95%CI 1.18-3.31)。
  • BMI正常分类可能不足以代表绝经后女性乳腺癌风险。

核心结论

  • 在BMI正常的绝经后女性中,相对较高的体脂水平与浸润性乳腺癌风险升高及循环代谢和炎症因子水平改变相关。
  • BMI正常分类可能不足以代表绝经后女性乳腺癌风险。

研究设计与样本

  • 妇女健康倡议(WHI)临床试验与观察性研究队列的二次分析,纳入BMI 18.5至24.9的绝经后女性。
  • 3460名50至79岁女性于1993年10月1日至1998年12月31日入组,在3个美国指定中心接受双能X线吸收法(DXA)体脂测量并随访。
  • 中位随访16年(范围9-20年),确诊182例浸润性乳腺癌,其中146例为ER阳性。
  • 随访截至2016年9月30日,数据分析时间为2017年8月2日至2018年8月21日。

主要发现

  • 纳入分析的3460名女性平均(SD)年龄63.6(7.6)岁。
  • 全身体脂最高四分位与最低四分位相比,浸润性乳腺癌多变量校正风险比HR 1.89(95%CI 1.21-2.95)。
  • 躯干脂肪最高四分位与最低四分位相比,浸润性乳腺癌多变量校正风险比HR 1.88(95%CI 1.18-2.98)。
  • ER阳性乳腺癌对应校正风险比分别为全身体脂HR 2.21(95%CI 1.23-3.67)、躯干脂肪HR 1.98(95%CI 1.18-3.31)。
  • 时间依赖协变量分析中系列DXA测量亦观察到相似的正相关。

关键数值与推荐

  • 躯干脂肪最高四分位与最低四分位相比,胰岛素、C反应蛋白、白细胞介素6、瘦素和甘油三酯水平更高,高密度脂蛋白胆固醇和性激素结合球蛋白水平更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Obesity is associated with an increased risk of breast cancer, including the estrogen receptor (ER)-positive subtype in postmenopausal women. Whether excess adiposity is associated with increased risk in women with a normal body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) is unknown. OBJECTIVE: To investigate the association between body fat and breast cancer risk in women with normal BMI. DESIGN, SETTING, AND PARTICIPANTS: This ad hoc secondary analysis of the Women's Health Initiative (WHI) clinical trial and observational study cohorts was restricted to postmenopausal participants with a BMI ranging from 18.5 to 24.9. Women aged 50 to 79 years were enrolled from October 1, 1993, through December 31, 1998. Of these, 3460 participants underwent body fat measurement with dual-energy x-ray absorptiometry (DXA) at 3 US designated centers with follow-up. At a median follow-up of 16 years (range, 9-20 years), 182 incident breast cancers had been ascertained, and 146 were ER positive. Follow-up was complete on September 30, 2016, and data from October 1, 1993, through September 30, 2016, was analyzed August 2, 2017, through August 21, 2018. MAIN OUTCOMES AND MEASURES: Body fat levels were measured at baseline and years 1, 3, 6, and 9 using DXA. Information on demographic data, medical history, and lifestyle factors was collected at baseline. Invasive breast cancers were confirmed via central review of medical records by physician adjudicators. Blood analyte levels were measured in subsets of participants. RESULTS: Among the 3460 women included in the analysis (mean [SD] age, 63.6 [7.6] years), multivariable-adjusted hazard ratios for the risk of invasive breast cancer were 1.89 (95% CI, 1.21-2.95) for the highest quartile of whole-body fat and 1.88 (95% CI, 1.18-2.98) for the highest quartile of trunk fat mass. The corresponding adjusted hazard ratios for ER-positive breast cancer were 2.21 (95% CI, 1.23-3.67) and 1.98 (95% CI, 1.18-3.31), respectively. Similar positive associations were observed for serial DXA measurements in time-dependent covariate analyses. Circulating levels of insulin, C-reactive protein, interleukin 6, leptin, and triglycerides were higher, whereas levels of high-density lipoprotein cholesterol and sex hormone-binding globulin were lower in those in the uppermost vs lowest quartiles of trunk fat mass. CONCLUSIONS AND RELEVANCE: In postmenopausal women with normal BMI, relatively high body fat levels were associated with an elevated risk of invasive breast cancer and altered levels of circulating metabolic and inflammatory factors. Normal BMI categorization may be an inadequate proxy for the risk of breast cancer in postmenopausal women. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00000611.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Iyengar NM, Arthur R, Manson JE, et al. Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study. JAMA Oncol. 2019. PMID: 30520976. doi:10.1001/jamaoncol.2018.5327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。